Puretech announces that imbrium therapeutics has exercised license option to lyt-503/imb-150 for interstitial cystitis/bladder pain syndrome

Boston--(business wire)--puretech announced that imbrium has exercised a license option under the companies' r&d collaboration agreement to develop puretech's lyt-503/imb-150.
PRTC Ratings Summary
PRTC Quant Ranking